OBJECTIVES: We estimated national and state-level potential medical care cost savings achievable through modest reductions in the prevalence of several diseases associated with the same lifestyle-related risk factors. METHODS: Using Medical Expenditure Panel Survey Household Component data (2003-2005), we estimated the effects on medical spending over time of reductions in the prevalence of diabetes, hypertension, and related conditions amenable to primary prevention by comparing simulated counterfactual morbidity and medical care expenditures to actual disease and expenditure patterns. We produced state-level estimates of spending by using multivariate reweighting techniques. RESULTS: Nationally, we estimated that reducing diabetes and hypertension prevalence by 5% would save approximately $9 billion annually in the near term. With resulting reductions in comorbidities and selected related conditions, savings could rise to approximately $24.7 billion annually in the medium term. Returns were greatest in absolute terms for private payers, but greatest in percentage terms for public payers. State savings varied with demographic makeup and prevailing morbidity. CONCLUSIONS: Well-designed interventions that achieve improvements in lifestyle-related risk factors could result in sufficient savings in the short and medium term to substantially offset intervention costs.
OBJECTIVES: We estimated national and state-level potential medical care cost savings achievable through modest reductions in the prevalence of several diseases associated with the same lifestyle-related risk factors. METHODS: Using Medical Expenditure Panel Survey Household Component data (2003-2005), we estimated the effects on medical spending over time of reductions in the prevalence of diabetes, hypertension, and related conditions amenable to primary prevention by comparing simulated counterfactual morbidity and medical care expenditures to actual disease and expenditure patterns. We produced state-level estimates of spending by using multivariate reweighting techniques. RESULTS: Nationally, we estimated that reducing diabetes and hypertension prevalence by 5% would save approximately $9 billion annually in the near term. With resulting reductions in comorbidities and selected related conditions, savings could rise to approximately $24.7 billion annually in the medium term. Returns were greatest in absolute terms for private payers, but greatest in percentage terms for public payers. State savings varied with demographic makeup and prevailing morbidity. CONCLUSIONS: Well-designed interventions that achieve improvements in lifestyle-related risk factors could result in sufficient savings in the short and medium term to substantially offset intervention costs.
Authors: Lawrence J Appel; Michael W Brands; Stephen R Daniels; Njeri Karanja; Patricia J Elmer; Frank M Sacks Journal: Hypertension Date: 2006-02 Impact factor: 10.190
Authors: S M Grundy; G J Balady; M H Criqui; G Fletcher; P Greenland; L F Hiratzka; N Houston-Miller; P Kris-Etherton; H M Krumholz; J LaRosa; I S Ockene; T A Pearson; J Reed; R Washington; S C Smith Journal: Circulation Date: 1998-05-12 Impact factor: 29.690
Authors: Frank B Hu; Meir J Stampfer; Steven M Haffner; Caren G Solomon; Walter C Willett; JoAnn E Manson Journal: Diabetes Care Date: 2002-07 Impact factor: 19.112
Authors: Steven G Aldana; Roger L Greenlaw; Hans A Diehl; Audrey Salberg; Ray M Merrill; Seiga Ohmine; Camille Thomas Journal: Prev Chronic Dis Date: 2005-12-15 Impact factor: 2.830
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2011-12-15 Impact factor: 29.690
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; David Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Graham Nichol; Nina P Paynter; Pamela J Schreiner; Paul D Sorlie; Joel Stein; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2012-12-12 Impact factor: 29.690
Authors: Thanh-Nghia Nguyen; Jeffrey Trocio; Stacey Kowal; Cheryl P Ferrufino; Julie Munakata; Dell South Journal: Am Health Drug Benefits Date: 2016-12
Authors: Rachna S Patel; Kamal H Sharma; Nitisha A Kamath; Nirav H Patel; Ankita M Thakkar Journal: Indian J Pharmacol Date: 2014 Sep-Oct Impact factor: 1.200
Authors: Kevin A Matthews; James Holt; Anne H Gaglioti; Kim A Lochner; Carla Shoff; Lisa C McGuire; Kurt J Greenlund Journal: Prev Chronic Dis Date: 2016-12-01 Impact factor: 2.830